HK1218628A1 - 用於促進生成原卟啉 的藥物組合物 - Google Patents

用於促進生成原卟啉 的藥物組合物

Info

Publication number
HK1218628A1
HK1218628A1 HK16106643.0A HK16106643A HK1218628A1 HK 1218628 A1 HK1218628 A1 HK 1218628A1 HK 16106643 A HK16106643 A HK 16106643A HK 1218628 A1 HK1218628 A1 HK 1218628A1
Authority
HK
Hong Kong
Prior art keywords
protoporphyrin
medicinal composition
promoting synthesis
promoting
synthesis
Prior art date
Application number
HK16106643.0A
Other languages
English (en)
Inventor
石塚昌宏
太田麗
神谷敦子
高橋究
田中彻
小澤俊幸
森本訓行
渡邊圭太郎
Original Assignee
Sbi Pharmaceuticals Co Ltd
Univ Osaka City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Pharmaceuticals Co Ltd, Univ Osaka City filed Critical Sbi Pharmaceuticals Co Ltd
Publication of HK1218628A1 publication Critical patent/HK1218628A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/00615-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/40Peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16106643.0A 2013-06-19 2016-06-08 用於促進生成原卟啉 的藥物組合物 HK1218628A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013129057 2013-06-19
PCT/JP2014/065813 WO2014203833A1 (ja) 2013-06-19 2014-06-13 プロトポルフィリンix生成促進用医薬組成物

Publications (1)

Publication Number Publication Date
HK1218628A1 true HK1218628A1 (zh) 2017-03-03

Family

ID=52104568

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16106643.0A HK1218628A1 (zh) 2013-06-19 2016-06-08 用於促進生成原卟啉 的藥物組合物
HK16110042.9A HK1221904A1 (zh) 2013-06-19 2016-08-23 用於促進生成原卟啉 的藥物組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16110042.9A HK1221904A1 (zh) 2013-06-19 2016-08-23 用於促進生成原卟啉 的藥物組合物

Country Status (11)

Country Link
US (1) US9603928B2 (zh)
EP (1) EP3011972B1 (zh)
JP (1) JP6051305B2 (zh)
CN (2) CN105555312A (zh)
DK (1) DK3011972T3 (zh)
ES (1) ES2755303T3 (zh)
HK (2) HK1218628A1 (zh)
HU (1) HUE046458T2 (zh)
PL (1) PL3011972T3 (zh)
PT (1) PT3011972T (zh)
WO (1) WO2014203833A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046458T2 (hu) 2013-06-19 2020-03-30 Sbi Pharmaceuticals Co Ltd Gyógyászati készítmény protoporfirin IX szintézisének elõsegítésére
EP3344246A4 (en) * 2015-08-31 2019-04-10 The University of Adelaide METHODS AND PRODUCTS FOR PREVENTING AND / OR TREATING INFECTIONS OF MICROORGANISMS COMPRISING IRON CHELATORS AND PORPHYRINS WITHOUT IRON
BR112020003259A2 (pt) * 2017-08-16 2020-08-18 Suncor Energy Inc. inibição fotodinâmica de patógenos microbianos em plantas
CN109821017A (zh) * 2019-03-20 2019-05-31 天津医科大学 5-氨基酮戊酸和铁螯合剂在制备抗肿瘤联合用药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07133277A (ja) 1993-11-09 1995-05-23 Yamanouchi Pharmaceut Co Ltd カルバペネム誘導体
US5895786A (en) * 1996-05-08 1999-04-20 New York Blood Center, Inc. Method for treating viral infections
GB0118251D0 (en) * 2001-07-26 2001-09-19 Photocure Asa Method
EA013402B1 (ru) * 2004-06-07 2010-04-30 Зингента Партисипейшнс Аг Способы уменьшения повреждения нематодами
JP5535808B2 (ja) * 2010-07-28 2014-07-02 富士フイルム株式会社 アスタキサンチン含有水系組成物、化粧料、及びアスタキサンチンの分解抑制方法
HUE046458T2 (hu) 2013-06-19 2020-03-30 Sbi Pharmaceuticals Co Ltd Gyógyászati készítmény protoporfirin IX szintézisének elõsegítésére

Also Published As

Publication number Publication date
PL3011972T3 (pl) 2020-02-28
DK3011972T3 (da) 2019-11-04
JP6051305B2 (ja) 2016-12-27
PT3011972T (pt) 2019-11-20
ES2755303T3 (es) 2020-04-22
EP3011972A4 (en) 2017-03-01
US20160136274A1 (en) 2016-05-19
CN112057627A (zh) 2020-12-11
JPWO2014203833A1 (ja) 2017-02-23
WO2014203833A1 (ja) 2014-12-24
HK1221904A1 (zh) 2017-06-16
EP3011972A1 (en) 2016-04-27
CN105555312A (zh) 2016-05-04
EP3011972B1 (en) 2019-10-23
US9603928B2 (en) 2017-03-28
HUE046458T2 (hu) 2020-03-30

Similar Documents

Publication Publication Date Title
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
HK1216175A1 (zh) 治療性化合物和組合物
HK1213798A1 (zh) 治療性化合物和組合物
HK1213818A1 (zh) 依帕列淨的治療用途
HUE044611T2 (hu) Gyógyászati készítmény rák kezelésére
PT2824114T (pt) Composição farmacêutica para o tratamento do cancro
IL264259A (en) Oral formulations of pyrrolidine derivatives
HK1217443A1 (zh) 用於糖尿病的口服治療的藥物組合物
EP2953605A4 (en) USE OF A COSMETIC COMPOSITION
IL245771A0 (en) Synthesis and compositions of porphyrin compounds
LT2812013T (lt) Kompozicija, skirta džs gydymui
PL2991618T3 (pl) Stabilna kompozycja farmaceutyczna o wysokim stężeniu lewoleukoworyny
HK1221904A1 (zh) 用於促進生成原卟啉 的藥物組合物
HRP20182110T1 (hr) Sastav spojeva tiakumicina
KR102216470B9 (ko) 천연물 조성물
IL240119A0 (en) Pharmaceutical compositions for oral treatment of diabetes